Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
| ▸ | GABRE | P78334 | 1/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995799 | 0.85 | CLK4 (0.44) | MYCXDHABCG2CHEK1NPY5R | |
| SCHEMBL29598148 | 0.85 | CLK4 (0.44) | MYCXDHABCG2CHEK1NPY5R | |
| SCHEMBL6461001 | 0.85 | — | — | |
| SCHEMBL451669 | 0.74 | — | — | |
| SCHEMBL2173234 | 0.73 | MYC (0.36) | MYCXDHABCG2GABRA1GABRG2 | |
| SCHEMBL31133396 | 0.73 | MYC (0.62) | MYCXDHABCG2CHEK1NPY5R | |
| SCHEMBL9792895 | 0.73 | MYC (0.62) | MYCXDHABCG2CHEK1NPY5R | |
| SCHEMBL6009491 | 0.73 | CCR1 (0.42) | — | |
| SCHEMBL131627 | 0.71 | — | — | |
| SCHEMBL1145922 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023212510-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | PRAETEGO INC (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230338344-A1 | AMPK Activators and Methods of Use Thereof | BIOVERATIV THERAPEUTICS INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4221700-A1 | AMPK ACTIVATORS AND METHODS OF USE THEREOF | Bioverativ Therapeutics Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4007632-A1 | INHIBITORS OF ADVANCED GLYCATION END PRODUCTS | Praetego, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| CN-114502546-A | Inhibitors of advanced glycation endproducts | 普拉特戈公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20210163450-A1 | Inhibitors of Advanced Glycation End Products | PRAETEGO INC | 2021-06-03 | — | — | US | disclosed |
| WO-2021022215-A1 | INHIBITORS OF ADVANCED GLYCATION END PRODUCTS | KHALIFAH RAJA G (US) | 2021-02-04 | — | — | WO | disclosed |
| US-9783527-B2 | Indazole ureas and method of use | ABBVIE INC. (US) | 2017-10-10 | — | — | US | disclosed |
| EP-2024349-B1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3194404-A1 | INDAZOLE UREAS AND METHOD OF USE | AbbVie Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2007038058-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| EP-1740579-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006083673-A2 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF C-JUN N-TERMINAL KINASES | ABBOTT LABORATORIES (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005095387-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | XIN ZHILI (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | KOSOGOF CHRISTI (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | CHRNA7, CHRNA5, CHRNA1 | MYC 4149/4885XDH 888/4885ABCG2 890/4885 |
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | MAPKAPK3, MAP3K3, MAPK3 | MYC 266/4885XDH 2817/4885ABCG2 3924/4885 |
| US-20230338344-A1 | AMPK Activators and Methods of Use Thereof | PRKAG2, PRKAG3, PRKAG1 | MYC 2566/4885XDH 1907/4885ABCG2 3887/4885 |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | MYC 3769/4885XDH 1516/4885ABCG2 3114/4885 |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | MYC 3710/4885XDH 1852/4885ABCG2 2800/4885 |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | MYC 541/4885XDH 1724/4885ABCG2 831/4885 |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | GPR119, GIPR, GCGR | MYC 1916/4885XDH 1347/4885ABCG2 2581/4885 |
| US-20210163450-A1 | Inhibitors of Advanced Glycation End Products | AGER, GLA, GPR119 | MYC 2749/4885XDH 825/4885ABCG2 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.